

Beit Haemek, Israel, June 28, 2021

Sartorius opens new cell culture media production site in Beit Haemek

- Focus on specialty and customized cell culture media, particularly for the advanced therapies market
- Beit Haemek will serve as the main production site for liquid media and buffers

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, will open its new site today in Beit Haemek, Israel, which focuses on specialty and customized cell culture media, particularly for the advanced therapies market. With the expansion, the plant will be able to produce nearly five times its current output. The new facility has been designed to meet the highest manufacturing and regulatory standards. It covers 11,800 square feet, or some 1,000 square meters, and includes Grades B and C cleanrooms as well as on-site equipment.

“The team in Israel has a long track record and experience in the advanced therapies market – from development to the production and sale of cell culture solutions. With the new state-of-the-art facility in Beit Haemek, we can build on this expertise and leverage the existing infrastructure to further grow this business,” said René Fáber, Head of the Bioprocess Solutions Division of Sartorius and member of the Executive Board.

To prepare for future demand, the existing facility will be upgraded as well. There are two parallel manufacturing lines to ensure that expected capacities can be reached. Sartorius will also accordingly increase the production staff on site. In addition, Beit Haemek will serve as Sartorius’ main production site for liquid media and buffers, complementary to the manufacturing capacities for powder media in Yauco, Puerto Rico.

Background: Sartorius acquired cell culture media production business from Biological Industries in 2019. Integration of this product segment has been essential in Sartorius’ key initiative to further develop its business and expertise in the advanced therapies segment.

Current image files

<https://www.sartorius.com/en/company/newsroom/downloads-publications>

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services

Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60 manufacturing and sales sites, serving customers around the globe.

Contact

Timo Lindemann

Corporate Communications

+49 (0)551.308.4724

timo.lindemann@sartorius.com

sartorius.com

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn.